ArticleKidney medicine2026
Biopsy Morphometrics as Predictors of Treatment Response in Primary Nephrotic Syndrome.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Defining Complete Remission in Nephrotic Syndrome: One Size May Not Fit All.Kidney medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Clinical outcome of primary nephrotic syndrome (PNS) is highly variable, and predicting an individual patient's treatment response remains difficult. PNS is characterized by means of podocyte injury and loss. We hypothesized that histologic parameters related to podocyte depletion predict treatment response. Study Design: Retrospective cohort study. Setting & Participants: We analyzed biopsy tissue of 106 patients with PNS (minimal change disease, N = 26; focal segmental glomerulosclerosis, N = 21; and membranous nephropathy [MN], N = 59) and 9 controls. Minimal change disease and focal segmental glomerulosclerosis were considered manifestations of the same entity, defined as idiopathic nephrotic syndrome (iNS), and analyzed as one group. Patients' baseline clinical and follow-up data were recorded. Kidney biopsies, stained for podocyte-specific and fibrosis markers, were quantitatively analyzed. Predictors: Glomerular density, glomerulosclerosis, podocyte number, podocyte density, and cortical fibrosis. Outcomes: Complete remission (CR) and delayed treatment response. Analytical Approach: Odds ratios and receiver operating characteristic-the area under the curve (ROC-AUC) values identified predictors. Results: In patients with iNS, the respective partial remission and CR rates were 29% and 60% during a median follow-up of 40 months. The majority of patients received high-dose corticosteroid treatment. Quantitation of cortical fibrosis had the highest discriminative power (ROC-AUC value, 0.79; 95% CI, 0.655-0.923) to predict CR. Other significant predictors included podocyte density, nonsclerotic glomerular density, and percentage of nonsclerotic glomeruli.In patients with MN, respective partial remission and CR rates were 41% and 54% during a median follow-up of 50 months. The percentage of nonsclerotic glomeruli and nonsclerotic glomerular density were predictors for CR (patients receiving immunosuppressive treatment [ROC-AUC value, 0.71; 95% CI, 0.535-0.893]; patients receiving nonimmunosuppressive treatment alone [ROC-AUC value, 0.80; 95% CI, 0.584-1.000]). Limitations: Relatively small cohorts prevented the use of covariates. Conclusions: In patients with iNS, higher podocyte density and nonsclerotic glomerular density, and lower glomerulosclerosis and cortical fibrosis predicted CR. In patients with MN, lower glomerulosclerosis and higher nonsclerotic glomerular density predicted CR. Biopsy parameters may thus be useful for estimating proteinuria outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.